Rho-Kinase/ROCK as a Potential Drug Target for Vitreoretinal Diseases
Rho-associated kinase (Rho-kinase/ROCK) was originally identified as an effector protein of the G protein Rho. Its involvement in various diseases, particularly cancer and cardiovascular disease, has been elucidated, and ROCK inhibitors have already been applied clinically for cerebral vasospasm and...
Saved in:
Main Authors: | Muneo Yamaguchi, Shintaro Nakao, Mitsuru Arima, Iori Wada, Yoshihiro Kaizu, Feng Hao, Shigeo Yoshida, Koh-hei Sonoda |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2017-01-01
|
Series: | Journal of Ophthalmology |
Online Access: | http://dx.doi.org/10.1155/2017/8543592 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Molecular Mechanisms of Alzheimer’s Disease Induced by Amyloid-β and Tau Phosphorylation Along with RhoA Activity: Perspective of RhoA/Rho-Associated Protein Kinase Inhibitors for Neuronal Therapy
by: Eun Hee Ahn, et al.
Published: (2025-01-01) -
Effects of the Rho-Kinase Inhibitor Y-27632 on Extraocular Muscle Surgery in Rabbits
by: Ji‐Sun Moon, et al.
Published: (2017-01-01) -
Crosstalk between Substrates and Rho-Associated Kinase Inhibitors in Cryopreservation of Tissue-Engineered Constructs
by: Arindam Bit, et al.
Published: (2017-01-01) -
Advances in Vitreoretinal Interface Disorders
by: Irini Chatziralli, et al.
Published: (2017-01-01) -
Hepatocyte Rho-associated kinase signaling is required for mice to survive experimental porphyria-associated liver injury
by: Jessica M. Herrera, et al.
Published: (2025-02-01)